Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Newly Diagnosed Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 750 (planned)
- Started
- Jun 26, 2026
- Main results expected
- Jan 11, 2029
- Fully finished
- May 12, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd.
Measured over: Up to 9 years.
MRD negative CR rate at 9M in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd
Measured over: Up to 9 years.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07764978 · record last updated 2026-08-14 · checked 2026-11-09 15:47 UTC